1998
Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4+ Cell Count
Vlahov D, Graham N, Hoover D, Flynn C, Bartlett J, Margolick J, Lyles C, Nelson K, Smith D, Holmberg S, Farzadegan H. Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4+ Cell Count. JAMA 1998, 279: 35-40. PMID: 9424041, DOI: 10.1001/jama.279.1.35.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBiomarkersBlack or African AmericanCD4 Lymphocyte CountDisease ProgressionFemaleHIV-1HumansMalePrognosisProportional Hazards ModelsProspective StudiesRegression AnalysisRNA, ViralSubstance Abuse, IntravenousSurvival AnalysisViral LoadConceptsInfectious disease deathsInjection drug usersPlasma viral loadViral loadDisease deathsCell countDrug usersPrognostic indicatorHuman immunodeficiency virus type 1 (HIV-1) viral loadAfrican American injection drug usersPlasma HIV-1 RNAHIV-1 viral loadInfectious diseasesClinical AIDS diagnosisLevels of CD4Kaplan-Meier analysisHIV-1 RNAPrognosis of personsPowerful prognostic informationProportional hazards modelCases of AIDSGood predictive valueCell count measurementsMedian followCohort study
1996
Alcohol Use and T‐Lymphocyte Subsets among Injection Drug Users with HIV‐1 Infection: A Prospective Analysis
Crum R, Galai N, Cohn S, Celentano D, Vlahov D. Alcohol Use and T‐Lymphocyte Subsets among Injection Drug Users with HIV‐1 Infection: A Prospective Analysis. Alcohol Clinical And Experimental Research 1996, 20: 364-371. PMID: 8730231, DOI: 10.1111/j.1530-0277.1996.tb01654.x.Peer-Reviewed Original ResearchConceptsInjection drug usersCohort of IDUsT lymphocyte subsetsDrinks/weekHIV seroconversionAlcohol useYears postseroconversionDrug usersAlcohol categoriesHIV-positive injection drug usersCD8 absolute countsHIV-1 seroconvertersProgression of immunodeficiencyLevels of CD4Intravenous drug useT lymphocyte subpopulationsFirst prospective studyHIV-1 infectionTime of seroconversionSignificant differencesEarly intervention programsHIV infectionHIV progressionOutpatient clinicProspective study